

# You are invited!

## Clinical Conversations in the Management of ADHD

The focus of the learning program will be on:

### ADHD and Comorbid Conditions

#### LEARNING OBJECTIVES

At the end of this section, you should be able to:

- Discuss the prevalence of the most common comorbidities in children and adults with attention deficit-hyperactivity disorder (ADHD) and how that prevalence varies with age.
- Identify those symptoms that overlap between ADHD and comorbid conditions and those that differentiate from these conditions.
- Apply treatment recommendations for ADHD patients who have most common comorbidities.

#### PROGRAM DETAILS

##### Speaker:

Dr. Pratap Chokka, MD, FRCPC  
Founder and CEO, Chokka Center for Integrative Health,  
Clinical Professor of Psychiatry, University of Alberta,  
Edmonton, AB

##### Date:

Tuesday, July 12, 2022

##### Time:

Agenda

6:45-7:00pm Login and Check Online Connection

7:00-8:30pm Scientific Presentation

#### EDITORIAL BOARD

**Doron Almagor, MD, FRCPC**  
Toronto, Ontario

**Joan Flood, MD**  
Scarborough, Ontario

**Evangelia Amirali, MD**  
**MMgmt (IMHL), FRCPC, FAPA**  
Montreal, Quebec

#### VIRTUAL MEETING DETAILS

Click [HERE](#) to register

Or go to [www.zoom.us/join](http://www.zoom.us/join) with  
Meeting ID: **935 0291 8713**

##### RSVP to:

Cathy Dawson

##### By:

July 10, 2022

##### E-mail:

Ccrawfo4@its.jnj.com

##### Telephone:

780-720-9203

#### THESE ACTIVITIES ARE SUPPORTED BY JANSSEN INC.

Under the guidance of the Innovative Medicines Canada code of conduct, this event is specifically designed for healthcare professionals involved and/or interested in the therapeutic management of psychiatry patient. *If you wish to opt-out of future email invitations to learning programs, please reply to this email and specify "unsubscribe" in the subject line*

Event registration and facilitation is provided by Zoom and information collected is governed by Zoom's Privacy Policy. Zoom will share your information with Janssen, and Janssen will use it for the purpose of running the event. A copy of Janssen's Privacy Policy can be found [here](#).

In order to promote a safe environment, conducive to working together in person, Janssen has created the following mandatory protocols that must be followed in advance of every in-person meeting. By accepting this Event invitation, you are attesting to:

- being fully vaccinated against COVID-19 (provided the vaccination is approved by Health Canada, and administered two weeks (14 days) after a second dose in a 2-dose vaccination series or two weeks (14 days) after a single-dose vaccine), or
- if you are unable or unwilling to attest to being fully vaccinated, you consent to: i) take a COVID-19 Rapid Antigen Test (taken in advance and not more than 24 hour before arriving at the Event) and (ii) to refrain from attending the Event unless a negative test result is obtained. In addition, you agree to comply with any provincially required screening, mask use, hand hygiene and distancing guidelines in addition to all other requirements in place at the non-J&J site hosting the Event.